SLC22A3 and colorectal carcinoma: For example, in a retrospective study Gu et al. [20] found that high expression of SLC22A3 (OCT3) may be a protective factor for CRC patients postoperatively treated with FOLFOX6 as a first-line adjuvant chemotherapy.